Goldman Sachs analyst Chris Hallam maintained a Buy rating on Deutsche Bank AG (DB – Research Report) today and set a price target of €22.70.

Wall Street investment bank Goldman Sachs is a man down in its small-cap equity research team. Street Talk understands analyst Chris Gawler left the building in the weeks after Goldman posted its biggest quarterly profit in three years and set bonuses.

Goldman Sachs analyst Michele Della Vigna maintained a Buy rating on Shell (UK) (SHEL – Research Report) today. The company’s shares opened

RBC Capital Markets showed confidence in American Express Company (NYSE:AXP) by increasing its price target from $330.00 to $350.00 while reiterating an Outperform rating on the stock. The adjustment follows the company’s recent fourth-quarter earnings report,

This team employs a bottom-up approach, looking for businesses capable of earning a return above their cost of capital ... Sachs India Equity. The duo also comanages Goldman Sachs ESG Emerging ...

Goldman Sachs and Macquarie have emerged as the top mergers and acquisitions (M&A) financial advisers in the metals and mining sector for 2024, in terms of value and volume, respectively, according to the latest league table by data and analytics company GlobalData.

Inside the careers, accomplishments, and clients of Goldman's new heads of investment banking: Kim Posnett, Matt McClure, and Anthony Gutman.

Alexandria Real Estate Equities, Inc. ("Alexandria" or the "Company") today announced that it is commencing an underwritten public offering, subject to market conditions, of senior notes (the "notes").

ServiceNow provided solid fourth quarter results, but shares sank 12% during Thursday trading as more meaningful revenue growth looks pushed out to the second half of 2025. Read more here.

Boeing Company (NYSE: BA) shares are trading lower Wednesday following the company's fourth-quarter earnings report, which showed a drop in performance.

Analysts from firms such as Jefferies, RBC Capital Markets, and Morgan Stanley (NYSE ... including the appointment of David Acheson as Executive Vice President of Commercial. Goldman Sachs revised its rating for Apellis from Buy to Neutral, citing a ...

Jeffrey Eisele, the Chief Development Officer at Apellis Pharmaceuticals, Inc. (NASDAQ:APLS), a $3.8 billion market cap biopharmaceutical company, recently sold a portion of his holdings in the company.